From: Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review
A. Tumor suppression vs. cancer cell lines (in vivo/in vitro) | ||||||||
MSC | Breast cancer cell line | |||||||
MCF-7 | MDA-MB-231 | All cell lines | ||||||
BM/AT/UC | 17/ND/75 (75) | 0/ND/60 (85.7) | 36/20/56.3 (82) | |||||
All MSC | 36 | 46 | 34.4 | |||||
B. Tumor suppression vs. cell administration scheme (in vivo) | ||||||||
MSC | In vivo cell administration scheme | |||||||
Co-injection of MSC + cancer cells | Administration of MSC in established tumors | |||||||
BM/AT/UC | 11.8 (50)/10 (0)/ND | 64.7 (72.7)/50 (100)/64 (66.7) | ||||||
All MSC | 14.3 (25) | 61.5 (75) | ||||||
C. Tumor suppression vs. MSC: cancer cell ratio (in vivo) | ||||||||
MSC | MSC: cancer cell ratio (in vivo) | |||||||
MSC: cancer < 1 | MSC: cancer ≥ 1 | |||||||
BM/AT/UC | 36.4/33.3/71.2 | 25/12.5/66.7 | ||||||
All MSC | 45.8 | 30 | ||||||
D. | ||||||||
Consensus of in vivo cytotherapy experiments | ||||||||
Effect on tumor | MSC type | Mouse model | Admin. route | MSC dosage (millions) | Ratio (MSC to cancer cells) | Repeated dosing | Effector-target overlap period (days) | Total experiment duration (days) |
ANTI- (N = 19) | NA | NA | NA | 1 | 1:2 | NA | 22 ± 19 | 30 ± 23 |
PRO- (N = 27) | BM | Athymic/nude | s.c./s.c. | 1 | 1:1.35 | No repeat | 39 ± 22 | 40 ± 24 |